Pyrimethamine is listed as one of the top drugs on the World Health Organization's essential drugs list. Pyrimethamine selectively inhibits the Plasmodium form of dihydrofolate reductase and reduces the production of folic acid, which is necessary for the synthesis of Plasmodium's nucleic acid. The ability of pyrimethamine to cure protozoan infections and toxoplasma infections, an increase in the number of human immunodeficiency virus (HIV) patients worldwide, and immunosuppressed people at the risk of infection are some of the factors that are expected to drive the development of the pyrimethamine market during the forecast period.
The global pyrimethamine market is estimated to be valued at US$ 1,106.8 million in 2022 and expected to increase to US$ 1,655.1 Mn by 2030, witnessing a CAGR of 5.2% over the forecast period (2022-2030).
Figure 1. Global Pyrimethamine Market Share (%), By Region, 2022
The rising prevalence of toxoplasmosis infection is expected to drive the growth of the global pyrimethamine market.
Toxoplasmosis is an infection caused by a single-celled parasite called Toxoplasma gondii. The rising prevalence of toxoplasmosis infection is expected to drive the growth of the global pyrimethamine market. As per the sources of the Centers for Disease Control and Prevention (CDC) 2018, in the U.S., an estimated 11% of the 6-year-old population was infected with Toxoplasma gondii. In different places around the world, it is estimated that over 60% of people have been infected with Toxoplasma gondii. The infection rate is generally higher in areas with high heat, humidity, and lower altitudes, as oocysts survive better in these types of environments.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2021 | Market Size in 2022: | US$ 1,106.8 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 |
| Forecast Period 2022 to 2030 CAGR: | 5.2% | 2030 Value Projection: | US$ 1,655.1 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Vyera Pharmaceuticals, LLC, Cerovene Healthcare PVT LTD, GlaxoSmithKline plc, Impax Laboratories, Inc., NCBO BioPortal, Pfizer, Inc., PRN Pharmacal, SUDA Pharmaceuticals, Taj Accura Pharmaceuticals, TargetMo Chemicals Inc., Evaluate Ltd., and Abcam |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2. Global Pyrimethamine Market Share (%) Analysis, By Route of Administration, 2022
Global Pyrimethamine Market – Regional Analysis
North America is expected to dominate the global pyrimethamine market due to an increase in the number of cancer cases (as pyrimethamine can induce apoptosis of cancer cells) and chemotherapy procedures in the region. For instance, according to the 2019-2021 Cancer Survival and Treatment Data and Data Report released by the American Cancer Society, as of January 1, 2019, the estimated number of cancer cases in the U.S. was approximately 16,920,370.
Global Pyrimethamine Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries across the globe. The coronavirus (COVID 19) pandemic and consequent lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. The coronavirus pandemic has also hindered the development, production, and supply of medicines and other healthcare products and affected the growth of the healthcare business of many companies around the world. Therefore, during the forecast period, the impact of the COVID19 pandemic is also expected to limit the growth of the global pyrimethamine market.
Global Pyrimethamine Market: Restraint
Possible side effects associated with pyrimethamine include occasional and possibly serious hypersensitivity reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and homophenylalanine amines, which are expected to hamper the market growth. Also, the high cost of pyrimethamine is expected to restrain the global pyrimethamine market growth over the forecast period. For instance, the price of Daraprim (pyrimethamine) is very high. In 2018, the list price for a one-month supply (60 tablets) in the U.S. was almost US$45,000.
Key Players
Major players operating in the global pyrimethamine market include Vyera Pharmaceuticals, LLC, Cerovene Healthcare PVT. LTD, GlaxoSmithKline plc, Impax Laboratories, Inc., NCBO BioPortal, Pfizer, Inc., PRN Pharmacal, SUDA Pharmaceuticals, Taj Accura Pharmaceuticals, TargetMo Chemicals Inc., Evaluate Ltd., and Abcam.
Pyrimethamine is a medicine used to treat protozoan infections. Pyrimethamine belongs to a class of drugs known as antiparasitics. It works by killing parasites. It is commonly used as an antimalarial (for the treatment and prevention of malaria), as well as to treat Toxoplasma gondii infections, and it is also used in combination with the antibiotic sulfa sulfadiazine for the treatment of human immunodeficiency virus (HIV) positive people. Toxoplasmosis is a serious, life-threatening, and sometimes fatal infection. The Centers for Disease Control and Prevention (CDC) has recognized toxoplasmosis as one of the five neglected parasitic infections. A large number of people are infected with toxoplasmosis; however, only a few patients will have serious complications. The routes of transmission of Toxoplasma gondii infection are food, contact with animals (cats), water, soil, and others.
As pyrimethamine is resistant to many Plasmodium species, it is generally administered in conjunction with sulfa and folinic acid. Pyrimethamine has also been found to limit the expression of the gene for superoxide dismutase 1, a protein associated with amyotrophic lateral sclerosis.
Market Dynamics
The increasing number of HIV patients worldwide is anticipated to drive the growth of the global pyrimethamine market over the forecast period. For instance, according to the global HIV statistics fact sheet published by The Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2020, globally, there were 37.7 million (30.2 million–45.1 million) people living with HIV, out of which 36.0 million (28.9 million–43.2 million) were adults, 1.7 million (1.2 million–2.2 million) were children aged between 0–14 years, and 53% of all people living with HIV were women and girls.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients